Chemotype-dependent dissociation of binding affinity and functional potency in synthetic cannabinoids.

Kozell L.; Eshleman A.; Schutzer K.; Bloom S.; Wolfrum K.; Swanson T.; Schutzer W.; Janowsky A.; Abbas A. · The Journal of pharmacology and experimental therapeutics · 2026

**Background & Methods** This in vitro pharmacological review characterized 74 synthetic cannabinoid receptor 1 (CB1R) agonists across multiple chemotypes (PINACAs, BUTINACAs, PICAs, PRINACAs, and related scaffolds) with structural variation in headgroup, core, and N-alkyl tail chemistry. Researchers quantified equilibrium affinity (Ki), functional potency (EC50), and efficacy (Emax) using radioligand binding and functional assays to define structural determinants of ultrapotency. **Key Findings** • Marked dissociation between binding affinity and functional potency was observed across many compounds, with numerous synthetic cannabinoids displaying subnanomolar EC50 values (ultrapotent functional responses) despite moderate nanomolar binding affinity, indicating that equilibrium affinity alone cannot predict biological potency. • Structural analysis revealed a division of labor: indazole-based cores and optimal N-pentyl or 5-fluoropentyl tail chemistry primarily enhance binding stability and affinity, while headgroup chemistry is the key determinant of coupling efficiency and functional activation potency. • Matched headgroups across different scaffold types (PICA versus PINACA) demonstrated similar affinity-potency dissociation patterns, with PICAs showing uniformly lower absolute affinity and potency values, confirming that core structure governs binding parameters while headgroup governs activation efficiency. **Dosage & Administration** Not reported. **Safety & Adverse Effects** The abstract notes that synthetic cannabinoids are "frequently associated with severe toxicity and mortality" and are "responsible for severe toxicity and fatalities," but specific adverse effects or clinical toxicological data are not detailed in this abstract. **Evidence Quality** This is a systematic in vitro pharmacological characterization study with moderate-to-good internal validity for mechanistic understanding. Limitations include: (1) reliance on cell-based assays rather than in vivo models, which may not fully predict clinical toxicity; (2) focus on CB1R agonism without examination of off-target effects or other cannabinoid receptor subtypes; (3) limited translational data connecting in vitro potency to human toxicological outcomes; and (4) publication in 2026 limits independent verification. The study provides valuable mechanistic insights into synthetic cannabinoid structure-activity relationships but cannot directly establish clinical safety profiles. Evidence level: Pre-clinical mechanistic research.

More recent cannabis research